Expression of CD133-2 during the Courses of Acute Leukemia and Its Clinical Significance
10.3969/j.issn.1671-7414.2018.02.011
- VernacularTitle:CD133-2在急性白血病病程中的表达及意义
- Author:
Shu-Wen WANG
1
;
Hong-Xia YAO
;
Ruo RAO
Author Information
1. 海南省人民医院血液病研究室
- Keywords:
CD133-2;
acute leukemia;
flow cytometry
- From:
Journal of Modern Laboratory Medicine
2018;33(2):35-37
- CountryChina
- Language:Chinese
-
Abstract:
Objective To explore the expression of CD133-2 during the treatment course of acute leukemia(AL) and its clinical significance.Methods Used flow cytometry with direct immunofluorescence staining to analyze CD133-2 of 67 acute leukemia patients with different treatment courese.Results The CD133-2 positive rate (52.4％)and expression rate (23.9％±21.5％) in AL were significantly higher than those in control (0,2.2％ ±3.9％).The CD133-2 positive rates of cases for primary treatment group,CR group and recurrence group were 52.4 ％,0 and 40.0 ％ respcctively,and expression rates were 23.9％±21.5％,5.0％±6.0％ and 28.4％±25.6％ respectively.There were significant difference in the positive rate and expression rate of CD133-2 among the three group (x2 =12.777,F=5.906,P＜0.05).The CD133-2 positive rates and expression rates in primary treatment group and recurrence group were significantly higher than those in complete remission cases.CD133-2 positive rate of CD34 + group was obviously higher than that of CD34-group (40.5％ vs 7.1％,x2=8.636,P＜0.05),and the CR rate of CD133-2-/CD34-group was significantly higher than that of CD133-2+/CD34 +group (83.3％ vs 33.3％,x2=6.078,P＜0.05).Conclusion The expression of CD133-2 was correlated with CD34,and CD133/CD34 co-overexpression might be a bad prognostic factor of AL.CD133-2 can be used as one of the indicator of predicting recurrence and monitoring MRD.
